Novel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas

Proteasome inhibitors, such as bortezomib and carfilzomib, have shown efficacy in anti-cancer therapy in hematological diseases but not in solid cancers. Here, we found that liposarcomas (LPS) are susceptible to proteasome inhibition, and identified drugs that synergize with carfilzomib, such as sel...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cell Mol Life Sci
Glavni autori: Jeitany, Maya, Prabhu, Aishvaryaa, Dakle, Pushkar, Pathak, Elina, Madan, Vikas, Kanojia, Deepika, Mukundan, Vineeth, Jiang, Yan Yi, Landesman, Yosef, Tam, Wai Leong, Kappei, Dennis, Koeffler, H. Phillip
Format: Artigo
Jezik:Inglês
Izdano: Springer International Publishing 2020
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7904719/
https://ncbi.nlm.nih.gov/pubmed/32851475
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00018-020-03620-w
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items